Related Experiment Video

Updated: Aug 9, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K

Bromodomain and extraterminal protein-targeted probe enables tumour visualisation in vivo using positron emission

Catherine G Fitzgerald Dickmann1,2,3, Alexander F McDonald2,3, Nhi Huynh3

  • 1Bio21 Institute, The University of Melbourne, Parkville, VIC 3010, Australia. whitejm@unimelb.edu.au.

Chemical Communications (Cambridge, England)
|February 22, 2023
PubMed

Insights

Researchers developed a new fluorine-18 radiolabeled molecule, [18F]BiPET-2, for molecular imaging of Bromodomain and Extraterminal (BET) proteins. This novel tracer shows promise for glioblastoma research and cancer imaging applications.

Area of Science:

  • Oncology
  • Molecular Imaging
  • Epigenetics

Background:

  • Bromodomain and extraterminal (BET) proteins are epigenetic regulators implicated in cancer.
  • BET proteins are promising oncology drug targets.
  • Molecular imaging of BET proteins in cancer has not been achieved.

Purpose of the Study:

  • To develop a novel positron-emitting tracer for molecular imaging of BET proteins.
  • To evaluate the in vitro and preclinical efficacy of the novel tracer in glioblastoma models.

Main Methods:

  • Development of a novel molecule radiolabeled with fluorine-18 ([18F]BiPET-2).
  • In vitro characterization of [18F]BiPET-2.
  • Preclinical evaluation of [18F]BiPET-2 in glioblastoma models.

Main Results:

  • Successful development of [18F]BiPET-2, a novel fluorine-18 radiolabeled molecule.
  • Demonstrated in vitro properties of [18F]BiPET-2.
  • Showcased preclinical efficacy of [18F]BiPET-2 in glioblastoma models.

Conclusions:

  • [18F]BiPET-2 represents a novel molecular imaging tracer targeting BET proteins.
  • This tracer holds potential for advancing glioblastoma research and cancer imaging.

More Related Videos

Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers12:24

Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers

Published on: July 17, 2012

12.5K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.4K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
213